Companies Biogen Inc
Biogen (BIIB): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Biogen Inc’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers67th pct.Of 15 peer CEOs
CEO pay, last three years
- $4,069,913FY2023
- $24,166,665FY2024
- $23,646,004FY2025
CEO total pay was $23,646,004 in fiscal 2025, down from $24,166,665 in fiscal 2024.
FY2025: salary $1,727,885 · bonus $0 · stock awards $18,368,875 · option awards $0
Executives and directors
Christopher Viehbacher · CEOPriya Singhal · Head of DevelopmentRobin Kramer · CFOMichael McDonnell · ExecutiveNicole Murphy · ExecutiveSusan Alexander · General CounselCaroline D. Dorsa · Chair of the BoardEric K. Rowinsky · Independent DirectorJesus B. Mantas · Independent DirectorLloyd Minor · Independent DirectorMaria C. Freire · Independent DirectorMenelas Pangalos · Independent DirectorMonish Patolawala · Independent DirectorStephen A. Sherwin · Independent DirectorSusan K. Langer · Independent DirectorWilliam A. Hawkins · Independent Director
Frequently asked questions
Who was the highest-paid executive at Biogen Inc in fiscal 2025?
As disclosed, Christopher Viehbacher (President and Chief Executive Officer) was the highest-paid executive at Biogen Inc in fiscal 2025, with total compensation of $23,646,004.
How does Biogen Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Christopher Viehbacher's total compensation ranked at the 67th percentile of Biogen Inc's disclosed peer group.
What is Biogen Inc's CEO-to-median employee pay ratio?
As disclosed, Biogen Inc's CEO-to-median employee pay ratio was 113:1.
How did shareholders vote on Biogen Inc's executive compensation?
As disclosed, 93.67% of shareholders supported Biogen Inc's executive compensation in the latest say-on-pay vote.
How much does Biogen Inc spend in total on board compensation for fiscal 2025?
As disclosed, Biogen Inc reported total board compensation of $4,671,953 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Christopher Viehbacher | $1,727,885 | $0 | $18,368,875 | $0 | $3,190,875 | $0 | $358,369 | $23,646,004 |
| President and Chief Executive Officer | ||||||||
| Susan Alexander | 1,028,111 | 0 | 5,845,129 | 0 | 1,062,219 | 37,718 | 159,340 | 8,132,517 |
| Executive Vice President, Chief Legal Officer | ||||||||
| Nicole Murphy | 909,109 | 0 | 5,566,081 | 0 | 977,828 | 0 | 122,487 | 7,575,505 |
| Head of Pharmaceutical Operations and Technology | ||||||||
| Priya Singhal | 929,712 | 898 | 5,566,081 | 0 | 950,833 | 0 | 123,863 | 7,571,387 |
| Head of Development | ||||||||
| Robin Kramer | 759,617 | 0 | 4,173,781 | 0 | 788,252 | 0 | 84,934 | 5,806,584 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Michael McDonnell | 226,895 | 0 | 0 | 0 | 0 | 0 | 43,955 | 270,850 |
| Former Executive Vice President and Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Christopher Viehbacher | $23,646,004 | $24,166,665 | $4,069,913 | ↓ −520,661 |
| Susan Alexander | 8,132,517 | 6,505,829 | 6,703,852 | ↑ +1,626,688 |
| Nicole Murphy | 7,575,505 | 5,740,359 | 5,714,319 | ↑ +1,835,146 |
| Priya Singhal | 7,571,387 | 6,387,663 | — | ↑ +1,183,724 |
| Robin Kramer | 5,806,584 | — | — | — |
| Michael McDonnell | 270,850 | 6,826,734 | 7,167,601 | ↓ −6,555,884 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation philosophy is to reward executives for the creation of long-term stockholder value. We design performance-based executive compensation that rewards short-term achievements while maintaining accountability for long-term stockholder value creation. We also seek to maintain competitiveness with our peer group to enable us to attract and retain extraordinary leaders who perform at high levels and succeed in a demanding business environment.
| CEO STI target (% of salary) | 150% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Nicole Murphy | PSU | 2025-02-06 | 5,268 | 10,535 | — | 21,070 | $1,499,868 |
| Priya Singhal | RSU | 2025-02-06 | — | — | 14,050 | — | 2,000,299 |
| Robin Kramer | PSU | 2025-02-06 | 1,975 | 7,900 | — | 15,800 | 1,549,190 |
| Nicole Murphy | RSU | 2025-02-06 | — | — | 14,050 | — | 2,000,299 |
| Susan Alexander | PSU | 2025-02-06 | 2,766 | 11,065 | — | 22,130 | 2,169,847 |
| Priya Singhal | PSU | 2025-02-06 | 2,634 | 10,535 | — | 21,070 | 2,065,914 |
| Christopher Viehbacher | PSU | 2025-02-06 | 17,385 | 34,770 | — | 69,540 | 4,950,205 |
| Susan Alexander | PSU | 2025-02-06 | 5,533 | 11,065 | — | 22,130 | 1,575,324 |
| Robin Kramer | PSU | 2025-02-06 | 3,950 | 7,900 | — | 15,800 | 1,124,723 |
| Susan Alexander | RSU | 2025-02-06 | — | — | 14,750 | — | 2,099,958 |
| Christopher Viehbacher | PSU | 2025-02-06 | 8,693 | 34,770 | — | 69,540 | 6,818,397 |
| Priya Singhal | PSU | 2025-02-06 | 5,268 | 10,535 | — | 21,070 | 1,499,868 |
| Christopher Viehbacher | RSU | 2025-02-06 | — | — | 46,360 | — | 6,600,273 |
| Robin Kramer | RSU | 2025-02-06 | — | — | 10,535 | — | 1,499,868 |
| Nicole Murphy | PSU | 2025-02-06 | 2,634 | 10,535 | — | 21,070 | 2,065,914 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Nicole Murphy | $2,000,299 | $3,565,782 | $0 | 64.1% |
| Priya Singhal | 2,000,299 | 3,565,782 | 0 | 64.1% |
| Robin Kramer | 1,499,868 | 2,673,913 | 0 | 64.1% |
| Susan Alexander | 2,099,958 | 3,745,171 | 0 | 64.1% |
| Christopher Viehbacher | 6,600,273 | 11,768,602 | 0 | 64.1% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Robin Kramer | PSU | 395 | — | $69,516 |
| Robin Kramer | RSU | 789 | — | 138,856 |
| Robin Kramer | PSU | 790 | — | 139,032 |
| Susan Alexander | PSU | 1,091 | — | 192,005 |
| Nicole Murphy | PSU | 1,091 | — | 192,005 |
| Priya Singhal | PSU | 1,248 | — | 219,636 |
| Robin Kramer | RSU | 1,407 | — | 247,618 |
| Priya Singhal | RSU | 1,829 | — | 321,886 |
| Nicole Murphy | RSU | 2,102 | — | 369,931 |
| Susan Alexander | PSU | 2,183 | — | 384,186 |
| Nicole Murphy | PSU | 2,183 | — | 384,186 |
| Susan Alexander | RSU | 2,190 | — | 385,418 |
| Priya Singhal | PSU | 2,495 | — | 439,095 |
| Susan Alexander | RSU | 3,880 | — | 682,841 |
| Nicole Murphy | RSU | 3,880 | — | 682,841 |
| Priya Singhal | RSU | 4,434 | — | 780,340 |
| Christopher Viehbacher | PSU | 5,066 | — | 891,565 |
| Robin Kramer | PSU | 7,900 | — | 1,390,321 |
| Christopher Viehbacher | PSU | 10,133 | — | 1,783,307 |
| Robin Kramer | RSU | 10,535 | — | 1,854,055 |
| Priya Singhal | PSU | 10,535 | — | 1,854,055 |
| Nicole Murphy | PSU | 10,535 | — | 1,854,055 |
| Susan Alexander | PSU | 11,065 | — | 1,947,329 |
| Priya Singhal | RSU | 14,050 | — | 2,472,660 |
| Nicole Murphy | RSU | 14,050 | — | 2,472,660 |
| Susan Alexander | RSU | 14,750 | — | 2,595,853 |
| Christopher Viehbacher | RSU | 18,017 | — | 3,170,812 |
| Christopher Viehbacher | PSU | 34,770 | — | 6,119,172 |
| Christopher Viehbacher | RSU | 46,360 | — | 8,158,896 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Caroline D. DorsaIndependent · Board Chair · Compensation and Management Development · Not standing for re-election | $230,000 | $399,930 | $0 | $0 | — | $629,930 |
| William A. HawkinsIndependent · Audit · Corporate Governance | 162,500 | 299,947 | 0 | 0 | — | 462,447 |
| Jesus B. MantasIndependent · Compensation and Management Development (Chair) | 155,000 | 299,947 | 0 | 0 | 5,000 | 459,947 |
| Maria C. FreireIndependent · Corporate Governance · Compensation and Management Development | 155,000 | 299,947 | 0 | 0 | 2,500 | 457,447 |
| Eric K. RowinskyIndependent · Compensation and Management Development · Corporate Governance | 155,000 | 299,947 | 0 | 0 | — | 454,947 |
| Monish PatolawalaIndependent · Audit (Chair) | 147,500 | 299,947 | 0 | 0 | — | 447,447 |
| Lloyd MinorIndependent · Audit | 140,000 | 299,947 | 0 | 0 | — | 439,947 |
| Stephen A. SherwinIndependent · Audit | 140,000 | 299,947 | 0 | 0 | — | 439,947 |
| Menelas PangalosIndependent · Compensation and Management Development · Newly elected | 140,000 | 299,947 | 0 | 0 | — | 439,947 |
| Susan K. LangerIndependent · Compensation and Management Development | 140,000 | 299,947 | 0 | 0 | — | 439,947 |
| Christopher A. ViehbacherEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $125,000 |
|---|---|
| Annual equity retainer | $300,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 30,000 / 30,000 |
| Stock ownership guideline | 5x cash retainer (Chair: 5x combined Chair + Board retainer) |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $1,565,000 |
| Equity awards (grant-date value) | $3,099,453 |
| All other compensation | $7,500 |
| Total cost of the board | $4,671,953 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Biogen as a peer
Companies that benchmark against BIIB
27 companies name BIIB as a compensation peer
The list of companies that name BIIB as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
AMGN Amgen Inc.INCY Incyte CorporationMRNA Moderna, Inc.REGN Regeneron Pharmaceuticals, Inc.ABBV AbbVie Inc.BMY Bristol-Myers Squibb CompanyJAZZ Jazz Pharmaceuticals plcLLY Eli Lilly and CompanyVRTX Vertex Pharmaceuticals IncorporatedBMRN BioMarin Pharmaceutical Inc.NBIX Neurocrine Biosciences, Inc.GILD Gilead Sciences Inc.ALNY Alnylam Pharmaceuticals, Inc.UTHR United Therapeutics CorporationMRK Merck & Co, Inc.
Peer reciprocity
The companies Biogen Inc names as compensation peers that name it back in their own disclosed peer groups.
Amgen Inc. (AMGN)80Incyte Corporation (INCY)81Moderna, Inc. (MRNA)82Regeneron Pharmaceuticals, Inc. (REGN)83Jazz Pharmaceuticals plc (JAZZ)84BioMarin Pharmaceutical Inc. (BMRN)85Neurocrine Biosciences, Inc. (NBIX)86Gilead Sciences Inc. (GILD)87Alnylam Pharmaceuticals, Inc. (ALNY)88United Therapeutics Corporation (UTHR)89
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Eli Lilly and Company | 2025 | David Ricks | $1,700,000 | $23,325,000 | $0 | $6,485,500 | $36,698,337 |
| 2 | AbbVie Inc. | 2025 | Robert Michael | 1,700,000 | 13,268,456 | 3,199,154 | 5,200,000 | 32,530,984 |
| 3 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 4 | Gilead Sciences Inc. | 2025 | Daniel O'Day | 1,795,192 | 15,238,402 | 4,500,060 | 4,848,120 | 28,437,198 |
| 5 | Amgen Inc. | 2025 | Robert Bradway | 1,925,409 | 12,599,589 | 5,399,996 | 3,907,000 | 24,693,120 |
| 6 | Biogen Inc | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 7 | BioMarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 8 | Bristol-Myers Squibb Company | 2025 | Christopher Boerner | 1,586,346 | 16,061,399 | 0 | 3,754,684 | 21,879,919 |
| 9 | Vertex Pharmaceuticals Incorporated | 2025 | Reshma Kewalramani | 1,600,000 | 15,002,270 | 0 | 4,118,640 | 21,144,261 |
| 10 | Merck & Co, Inc. | 2025 | Robert Davis | 1,645,302 | 12,102,838 | 3,380,004 | 2,326,500 | 20,797,845 |
| 11 | Moderna, Inc. | 2025 | Stéphane Bancel | 1,677,739 | 6,897,455 | 6,897,425 | 4,302,360 | 19,932,217 |
| 12 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 13 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 14 | Alnylam Pharmaceuticals, Inc. | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 15 | Neurocrine Biosciences, Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 16 | Regeneron Pharmaceuticals, Inc. | 2025 | Leonard Schleifer | 1,979,922 | — | — | 3,682,655 | 7,280,549 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Biogen Inc | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| AbbVie Inc. | not disclosed | PSU 40 · PRSU 40 · Option 20 | Yes — Relative TSR | Semler Brossy |
| Alnylam Pharmaceuticals, Inc. | 200% | PSU 50 · RSU 25 · Option 25 | No | Pay Governance |
| Amgen Inc. | 136.0% | PSU 50 · Options 30 · RSU 20 | Yes — relative TSR | Frederic W. Cook & Co., Inc. (FW Cook) |
| BioMarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Bristol-Myers Squibb Company | 157.66% | PSU 60 · MSU 40 | Yes — 3-Year Relative TSR CAGR | Farient Advisors LLC |
| Eli Lilly and Company | 218% | PSU 100 | No | FW Cook |
| Gilead Sciences Inc. | 180% | PSU 50 · Option 25 · RSU 25 | Yes — Relative TSR | FW Cook |
| Incyte Corporation | 138.6% | PSU 60 · RSU 20 · Option 20 | Yes — relative total shareholder return (TSR) | Aon |
| Jazz Pharmaceuticals plc | 150% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon |
| Merck & Co, Inc. | 94% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (R-TSR) | FW Cook |
| Moderna, Inc. | 170% | PSU 50 · Options 50 | No | Pay Governance LLC |
| Neurocrine Biosciences, Inc. | 105% | Option 50 · PRSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Regeneron Pharmaceuticals, Inc. | 155% | Options 60 · RSU 40 | not disclosed | Pay Governance LLC |
| United Therapeutics Corporation | 221% | PSO 50 · PSU 50 | No | Aon |
| Vertex Pharmaceuticals Incorporated | not disclosed | PSU 55 · RSU 45 | No | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-09 | 114,184,816 | 7,454,737 | 267,869 | 93.67% | Passed |
| 2025 | 2025-06-17 | 78,531,756 | 37,113,368 | 364,062 | 67.91% | Passed |
| 2024 | 2024-06-20 | 114,367,799 | 5,054,473 | 138,358 | 95.77% | Passed |
| 2023 | 2023-06-26 | 82,640,454 | 36,292,390 | 191,733 | 69.48% | Passed |
| 2022 | 2022-06-15 | 60,099,277 | 55,305,837 | 493,730 | 51.85% | Passed |
| 2021 | 2021-06-02 | 59,401,387 | 56,206,071 | 4,667,218 | 49.39% | Failed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-09 | 93.67%a |
| 2025 | 2025-06-17 | 67.91%b |
| 2024 | 2024-06-20 | 95.77%c |
a. Approved under the standard stated in the filing — “Abstentions will have the effect of a vote against the proposal, and broker non-votes, if any, will not have any effect on the results of those deliberations.”.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, are not considered votes cast under our bylaws and will have no effect on the results of this vote.”.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, are not considered votes cast under our bylaws and will have no effect on the results of this vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 113 : 1 |
|---|---|
| CEO total compensation | $23,646,004 |
| Median employee compensation | $208,335 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dividend-equivalent accruals | 2026-05-01 | — | 939 | — | — | 1 insider, 1 accrual row | ||
| Adam Keeney | Head of Corporate Development | 2026-05-01 | D | 455 | 187 | 85,112 | Common | Form 4 ↗ |
| Adam Keeney | Head of Corporate Development | 2026-05-01 | A | 939 | 0 | 0 | Common | Form 4 ↗ |
| Monish Patolawala | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| Susan K. Langer | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| Menelas Pangalos | Director | 2026-06-09 | D | 2,370 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Menelas Pangalos | Director | 2026-06-09 | A | 2,370 | 0 | 0 | Common | Form 4 ↗ |
| Eric K. Rowinsky | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| Maria C. Freire | Director | 2026-06-09 | A | 2,005 | 0 | 0 | Common | Form 4 ↗ |
| Jesus B. Mantas | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| William A. Hawkins | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| Menelas Pangalos | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| Lloyd Minor | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| Lloyd Minor | Director | 2026-08-03 | D | 593 | 203 | 120,581 | Common | Form 4 ↗ |
| Lloyd Minor | Director | 2026-08-04 | D | 593 | 201 | 119,169 | Common | Form 4 ↗ |
| Michael Parini | Chief Legal Officer | 2026-09-01 | A | 7,405 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-01 | — | 985 | — | — | 1 insider, 1 accrual row | ||
| Sean Godbout | Chief Accounting Officer | 2026-10-02 | D | 8 | 220 | 1,759 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-02 | — | 27 | — | — | 1 insider, 1 accrual row | ||
| Sean Godbout | Chief Accounting Officer | 2026-10-02 | A | 27 | 0 | 0 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-10-30 | — | 695 | — | — | 1 insider, 1 accrual row | ||
| Jane Grogan | Head of Research | 2026-10-30 | D | 345 | 254 | 87,499 | Common | Form 4 ↗ |
| Jane Grogan | Head of Research | 2026-10-30 | A | 695 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 24 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Adam Keeney | Head of Corporate Development | 2026-05-01 | D | 939 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Adam Keeney | Head of Corporate Development | 2026-05-01 | D | 455 | 187 | 85,112 | Common | Form 4 ↗ |
| Adam Keeney | Head of Corporate Development | 2026-05-01 | A | 939 | 0 | 0 | Common | Form 4 ↗ |
| Monish Patolawala | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| Susan K. Langer | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| Menelas Pangalos | Director | 2026-06-09 | D | 2,370 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Menelas Pangalos | Director | 2026-06-09 | A | 2,370 | 0 | 0 | Common | Form 4 ↗ |
| Eric K. Rowinsky | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| Maria C. Freire | Director | 2026-06-09 | A | 2,005 | 0 | 0 | Common | Form 4 ↗ |
| Jesus B. Mantas | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| Stephen A. Sherwin | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| William A. Hawkins | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| Menelas Pangalos | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| Lloyd Minor | Director | 2026-06-09 | A | 1,505 | 0 | 0 | Common | Form 4 ↗ |
| Lloyd Minor | Director | 2026-08-03 | D | 593 | 203 | 120,581 | Common | Form 4 ↗ |
| Lloyd Minor | Director | 2026-08-04 | D | 593 | 201 | 119,169 | Common | Form 4 ↗ |
| Michael Parini | Chief Legal Officer | 2026-09-01 | A | 7,405 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Godbout | Chief Accounting Officer | 2026-10-01 | A | 985 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Godbout | Chief Accounting Officer | 2026-10-02 | D | 8 | 220 | 1,759 | Common | Form 4 ↗ |
| Sean Godbout | Chief Accounting Officer | 2026-10-02 | D | 27 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sean Godbout | Chief Accounting Officer | 2026-10-02 | A | 27 | 0 | 0 | Common | Form 4 ↗ |
| Jane Grogan | Head of Research | 2026-10-30 | D | 695 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jane Grogan | Head of Research | 2026-10-30 | D | 345 | 254 | 87,499 | Common | Form 4 ↗ |
| Jane Grogan | Head of Research | 2026-10-30 | A | 695 | 0 | 0 | Common | Form 4 ↗ |
Sources (89 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Christopher Viehbacher. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 52. As printed: 23,646,004. View filing ↗
- Section 01, Susan Alexander. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 52. As printed: 8,132,517. View filing ↗
- Section 01, Nicole Murphy. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 52. As printed: 7,575,505. View filing ↗
- Section 01, Priya Singhal. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 52. As printed: 7,571,387. View filing ↗
- Section 01, Robin Kramer. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 52. As printed: 5,806,584. View filing ↗
- Section 01, Michael McDonnell. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 52. As printed: 270,850. View filing ↗
- Section 03, Nicole Murphy PSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Priya Singhal RSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Robin Kramer PSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Nicole Murphy RSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Susan Alexander PSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Priya Singhal PSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Viehbacher PSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Susan Alexander PSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Robin Kramer PSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Susan Alexander RSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Viehbacher PSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Priya Singhal PSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Christopher Viehbacher RSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Robin Kramer RSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Nicole Murphy PSU. DEF 14A, filed 2026-04-28. Section “2025 Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-28. Section “CEO Pay Ratio”. As printed: 113 : 1. View filing ↗
- Section 08, Caroline D. Dorsa. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 629,930. View filing ↗
- Section 08, William A. Hawkins. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 462,447. View filing ↗
- Section 08, Jesus B. Mantas. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 459,947. View filing ↗
- Section 08, Maria C. Freire. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 457,447. View filing ↗
- Section 08, Eric K. Rowinsky. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 454,947. View filing ↗
- Section 08, Monish Patolawala. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 447,447. View filing ↗
- Section 08, Lloyd Minor. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 439,947. View filing ↗
- Section 08, Stephen A. Sherwin. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 439,947. View filing ↗
- Section 08, Menelas Pangalos. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 439,947. View filing ↗
- Section 08, Susan K. Langer. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 439,947. View filing ↗
- Section 08, Christopher A. Viehbacher. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Adam Keeney 2026-05-01. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Keeney 2026-05-01. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Adam Keeney 2026-05-01. Form 4, filed 2026-05-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Monish Patolawala 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Susan K. Langer 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Menelas Pangalos 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Menelas Pangalos 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric K. Rowinsky 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Maria C. Freire 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jesus B. Mantas 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephen A. Sherwin 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William A. Hawkins 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Menelas Pangalos 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lloyd Minor 2026-06-09. Form 4, filed 2026-06-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lloyd Minor 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lloyd Minor 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Parini 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean Godbout 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean Godbout 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean Godbout 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sean Godbout 2026-10-02. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jane Grogan 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jane Grogan 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jane Grogan 2026-10-30. Form 4, filed 2026-11-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-10. Item 5.07 · say-on-pay result. As reported: 93.67% (votes for as printed: 114,184,816). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-23. Item 5.07 · say-on-pay result. As reported: 67.91% (votes for as printed: 78,531,756). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-25. Item 5.07 · say-on-pay result. As reported: 95.77% (votes for as printed: 114,367,799). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 1,565,000 + equity 3,099,453 + all other 7,500 = 4,671,953, summed across the director compensation table rows.
- Eli Lilly and Company, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Eli Lilly and Company's own proxy. As printed: 36,698,337. View filing ↗
- AbbVie Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in AbbVie Inc.'s own proxy. As printed: 32,530,984. View filing ↗
- Incyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. View filing ↗
- Gilead Sciences Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Gilead Sciences Inc.'s own proxy. As printed: 28,437,198. View filing ↗
- Amgen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. View filing ↗
- Biogen Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Biogen Inc's own proxy. As printed: 23,646,004. View filing ↗
- BioMarin Pharmaceutical Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. View filing ↗
- Bristol-Myers Squibb Company, Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Bristol-Myers Squibb Company's own proxy. As printed: 21,879,919. View filing ↗
- Vertex Pharmaceuticals Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Vertex Pharmaceuticals Incorporated's own proxy. As printed: 21,144,261. View filing ↗
- Merck & Co, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-08. CEO total compensation as printed in Merck & Co, Inc.'s own proxy. As printed: 20,797,845. View filing ↗
- Moderna, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. View filing ↗
- Jazz Pharmaceuticals plc, Section 10b CEO total. DEF 14A, filed 2026-06-08. CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. View filing ↗
- United Therapeutics Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. View filing ↗
- Alnylam Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. View filing ↗
- Neurocrine Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. View filing ↗
- Regeneron Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. View filing ↗
- Section 10a, Amgen Inc. reciprocity. DEF 14A. Amgen Inc. names Biogen Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Incyte Corporation reciprocity. DEF 14A. Incyte Corporation names Biogen Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Moderna, Inc. reciprocity. DEF 14A. Moderna, Inc. names Biogen Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Regeneron Pharmaceuticals, Inc. reciprocity. DEF 14A. Regeneron Pharmaceuticals, Inc. names Biogen Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Jazz Pharmaceuticals plc reciprocity. DEF 14A. Jazz Pharmaceuticals plc names Biogen Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, BioMarin Pharmaceutical Inc. reciprocity. DEF 14A. BioMarin Pharmaceutical Inc. names Biogen Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Neurocrine Biosciences, Inc. reciprocity. DEF 14A. Neurocrine Biosciences, Inc. names Biogen Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Gilead Sciences Inc. reciprocity. DEF 14A. Gilead Sciences Inc. names Biogen Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity. DEF 14A. Alnylam Pharmaceuticals, Inc. names Biogen Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, United Therapeutics Corporation reciprocity. DEF 14A. United Therapeutics Corporation names Biogen Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗